Moderna, Pfizer's new race: The RSV vaccine FDA approval process
Publishing timestamp: 2023-01-18 17:32:45
Summary
Moderna and Pfizer have produced Covid-19 vaccines in record times, and are now working on RSV vaccines with mRNA technology that can compress the timeline for development from 8 years to 2 years. Both companies have released results from RSV vaccine trials with efficacy results strong enough to expect expedited approval from FDA. Pfizer has 19 products including five new vaccines in the next 18 months, and Moderna is filing for FDA approval for its vaccine soon. Both companies are also working on Covid vaccines and other vaccines for flu, RSV, pentavalent meningococcal disease, shingles, and Lyme disease. Wall Street is uncertain about the short-term business potential, but the companies expect utilization levels to be similar year over year. Over 700 million doses have been administered in the US and over 5 billion vaccine doses have been administered around the world.
Sentiment: POSITIVE
Keywords: pfizer inc, fda, immunizations, vaccinations, business news, moderna inc, respiratory syncytial virus, technology,
Source: https://www.cnbc.com/2023/01/18/moderna-pfizers-new-race-the-rsv-vaccine-fda-approval-process.html